Michelle Gilson
Stock Analyst at Morgan Stanley
(1.10)
# 3,837
Out of 5,090 analysts
31
Total ratings
32.14%
Success rate
-6.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michelle Gilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Upgrades: Overweight | $10 → $20 | $6.50 | +207.69% | 4 | Jan 9, 2025 | |
| CORT Corcept Therapeutics | Initiates: Buy | $30 | $86.11 | -65.16% | 1 | Feb 2, 2022 | |
| RZLT Rezolute | Maintains: Buy | $30 → $17 | $10.42 | +63.15% | 2 | Nov 29, 2021 | |
| ASND Ascendis Pharma | Maintains: Buy | $190 → $196 | $205.44 | -4.60% | 5 | Jun 1, 2021 | |
| TVTX Travere Therapeutics | Maintains: Buy | $48 → $45 | $35.00 | +28.57% | 3 | May 27, 2021 | |
| STOK Stoke Therapeutics | Maintains: Buy | $72 → $76 | $30.87 | +146.19% | 4 | Mar 11, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $95 → $91 | $53.40 | +70.41% | 12 | Mar 1, 2021 |
Vir Biotechnology
Jan 9, 2025
Upgrades: Overweight
Price Target: $10 → $20
Current: $6.50
Upside: +207.69%
Corcept Therapeutics
Feb 2, 2022
Initiates: Buy
Price Target: $30
Current: $86.11
Upside: -65.16%
Rezolute
Nov 29, 2021
Maintains: Buy
Price Target: $30 → $17
Current: $10.42
Upside: +63.15%
Ascendis Pharma
Jun 1, 2021
Maintains: Buy
Price Target: $190 → $196
Current: $205.44
Upside: -4.60%
Travere Therapeutics
May 27, 2021
Maintains: Buy
Price Target: $48 → $45
Current: $35.00
Upside: +28.57%
Stoke Therapeutics
Mar 11, 2021
Maintains: Buy
Price Target: $72 → $76
Current: $30.87
Upside: +146.19%
BioMarin Pharmaceutical
Mar 1, 2021
Maintains: Buy
Price Target: $95 → $91
Current: $53.40
Upside: +70.41%